1051
|
Puranen J, Laakso M, Riekkinen PJ, Sivenius J. Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke. J Cardiovasc Pharmacol 1998; 32:291-4. [PMID: 9700992 DOI: 10.1097/00005344-199808000-00017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We performed a subgroup analysis of the first European Stroke Prevention Study including 1,306 patients recruited in a single center, Kuopio, Finland, to investigate whether or not antiplatelet therapy is effective in the secondary prevention of stroke in hypertensive patients with transient ischemic attack (TIA) or stroke. The patients were treated with aspirin, 990 mg/day, plus dipyridamole, 225 mg/day, or placebo for 2 years. The patients with high systolic blood pressure (> or = 140 mm Hg; n = 1.105) or high diastolic blood pressure (> or = 85 mm Hg; n = 1,120) at entry, were classified into subgroups by blood pressure level. The effect of treatment was statistically significant in all subgroups with high systolic (end-point reduction, 55.2-68.2%) and diastolic blood pressure (end-point reduction, 47.3-82.1%). Risk reduction was, however, greatest in patients with the highest diastolic blood pressure. One possible explanation is that platelets are more activated in these patients, and this can be effectively prevented by antiplatelet therapy. Further studies are needed to confirm this hypothesis.
Collapse
Affiliation(s)
- J Puranen
- Department of Neurology, University of Kuopio, Finland
| | | | | | | |
Collapse
|
1052
|
|
1053
|
Abstract
Arterial thrombosis frequently leads to death or disability from stroke, peripheral arterial disease, or myocardial infarction (MI). Treating the underlying causes of these diseases is the key to producing significant reduction in morbidity, mortality, and health care costs. Prevention of arterial thrombosis is the primary indication for antiplatelet therapy, and intense research has been conducted in the past decade to develop novel antiplatelet agents with favorable safety profiles. The results of the Antiplatelet Trialists' Collaboration, which definitively established the rationale for antiplatelet agents in the prevention of death, MI, and stroke, were an important stimulus for this research. This large meta-analysis combined data from 145 randomized trials and showed that antiplatelet therapy (most commonly aspirin, 75 to 325 mg/d) reduced the risk of vascular events, including nonfatal MI, nonfatal stroke, and vascular death, by 25% in patients at high risk for occlusive vascular disease. The limitations and adverse effects associated with traditional antiplatelet agents such as aspirin have prompted the search for newer antiplatelet agents. Clinical trials such as the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study, which was the first study to evaluate aspirin and clopidogrel in patients with cerebrovascular, cardiac, and peripheral arterial disease, have established the importance of newer antiplatelet effects in the management of patients with diseases associated with atherosclerosis. The pathophysiology of atherosclerosis, the mechanisms of action of antiplatelet agents, and the results of these and other clinical trials that document the value of antiplatelet agents in atherosclerosis are reviewed in this paper.
Collapse
|
1054
|
Abstract
The peroxidation step of lipid transormation is considered to be essential in the pathogenesis of atherosclerosis. Although data concerning the mechanisms by which lipid peroxidation occurs in vivo are scarce, several lines of evidence suggest that some endogenous and exogenous compounds with antioxidant activity could have some beneficial effects in the prevention of atherosclerosis. Ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) act as the most important hydrophilic and lipophilic antioxidants, respectively in vivo. Accordingly, animal and human studies suggest that these compounds may have some preventive effect against the development of clinical coronary heart disease. Many plant phenols and flavonoids may be important dietary antioxidants and it has been speculated that these compounds in red wine or in the Mediterranean diet could explain the 'French paradox'. Several studies show that antioxidants such as probucol and butylated hydroxytoluene can inhibit development of atherosclerotic lesions in Watanabe and cholesterol-fed rabbits. Some drugs such as beta-blockers, calcium antagonists, hypolipodemic drugs,...appear to have at least in vitro antioxidant effects but the clinical relevance of these properties remains unkonwn. Moreover, some interventions aimed to decrease the LDL-oxidative susceptibility have not been shown to attenuate atherogenesis when cholesterol levels remain markedly elevated.
Collapse
Affiliation(s)
- F R Heller
- Department of Internal Medicine, Hopital de Jolimont, Belgium
| | | | | |
Collapse
|
1055
|
Abstract
There is limited evidence that dipyridamole is generally an effective antithrombotic agent when used alone, nor is there convincing evidence that the combination of aspirin and dipyridamole is more effective than aspirin alone, except perhaps in cerebrovascular disease. There is no consistent evidence to support the routine use of dipyridamole after coronary artery bypass grafting and in patients with occlusive peripheral vascular disease, although these remain common reasons for its use. Dipyridamole is a useful agent in 'pharmacological stress' testing in nuclear cardiology imaging and may be valuable when combined with warfarin in certain patient groups, such as those with prosthetic heart valves. When combined with aspirin, dipyridamole may be of value in the secondary prophylaxis of cerebrovascular disease, although further studies are clearly needed. In a significant proportion of cases, evidence-based medicine cannot support the current widespread continued prescription of dipyridamole in cardiological practice, but the jury is still out on cerebrovascular disease.
Collapse
Affiliation(s)
- C R Gibbs
- University Department of Medicine, City Hospital, Birmingham, England
| | | |
Collapse
|
1056
|
Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, Nakashima M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol 1998; 345:185-92. [PMID: 9600636 DOI: 10.1016/s0014-2999(98)00005-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We compared the antithrombotic effect of anti-GPIIb/IIIa antibody Fab fragment YM337 with that of a thromboxane A2 synthetase inhibitor, sodium ozagrel. With the monkeys under halothane anesthesia, the right middle cerebral artery was observed via a transorbital approach without cutting the dura mater. Photoillumination (wavelength 540 nm) was applied to the middle cerebral artery, and then rose bengal (20 mg kg(-1)) was administered intravenously. The experimental drugs were intravenously injected 15 min before rose bengal injection and followed by continuous infusion for 3 h after dye injection. The thrombotic occlusion induced by this photochemical reaction in monkey middle cerebral artery was reproducible. YM337 significantly prolonged the time to first occlusion and the total time of arterial patency during the 3-h observation period after dye injection. In contrast, sodium ozagrel had no significant effect. YM337 but not sodium ozagrel significantly inhibited ex vivo ADP-induced platelet aggregation. However, while sodium ozagrel significantly inhibited the thromboxane B2 generation accompanying arachidonic acid-induced platelet aggregation, YM337 had no effect on this variable. Neurological deficit in the YM337-treated animals was significantly milder than that in the control group. The area of infarct in the YM337 treatment animals was smaller than that in the control group. The novel selective GPIIb/IIIa antagonist YM337 was effective in ameliorating the decrease in patency of the middle cerebral artery and reducing the area of cerebral infarction in monkeys.
Collapse
Affiliation(s)
- S Kaku
- Department of Pharmacology, Hamamatsu University School of Medicine, Japan.
| | | | | | | | | | | | | |
Collapse
|
1057
|
Kelley RE. Stroke prevention and intervention. New options for improved outcomes. Postgrad Med 1998; 103:43-5, 49-50, 56-8 passim. [PMID: 9479307 DOI: 10.3810/pgm.1998.02.353] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Data from recent clinical studies have replaced the empiricism that once pervaded the medical literature regarding stroke. This has created exciting opportunities for optimal management as well as challenges related to the importance of early recognition and intervention. Dr Kelley reviews recent advances in prevention and treatment of stroke and describes a systematic approach that directly affects choice of diagnostic tests and therapeutic options.
Collapse
Affiliation(s)
- R E Kelley
- Department of Neurology, Louisiana State University Medical Center, Shreveport 71130-3932, USA.
| |
Collapse
|
1058
|
Abstract
Stroke disease remains a national priority due to the high morbidity and mortality. Good clinical practice dictates that risk factors are identified and corrected. Various therapeutic regimens have been tested in trials of sufficient strength to give answers. In the second European Stroke Prevention Study (ESPSZ), low dose aspirin (50 mg/d), sustained release dipyridamole (200 mg/d) were shown to reduce recurrence of stroke and TIA. The combination was twice as effective. Also in the Clopidogrel/aspirin Prevention of Recurrence of Ischaemic Events (CAPRIE) trial clopidogrel was shown to be superior to aspirin. In clinical practice patients with stroke or TIA should be investigated rapidly, their risk factors corrected and appropriate drug regimens implemented.
Collapse
Affiliation(s)
- C D Forbes
- Department of Medicine, Ninewells Hospital, Dundee
| |
Collapse
|
1059
|
Forbes CD. Secondary prevention of stroke--new trials. Scott Med J 1998; 43:5-6. [PMID: 9533250 DOI: 10.1177/003693309804300102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- C D Forbes
- Department of Medicine, Ninewells Hospital and Medical School, Dundee
| |
Collapse
|
1060
|
Gibbs CR, Li-Saw-Hee FL, Lip GY. Up to date review of the secondary preventive measures for recurrent ischaemic stroke and transient ischaemic episodes. Scott Med J 1998; 43:6. [PMID: 9533251 DOI: 10.1177/003693309804300103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
1061
|
Masuhr F, Busch M, Einhäupl KM. Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke 1998; 29:339-45. [PMID: 9472871 DOI: 10.1161/01.str.29.2.339] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND PURPOSE Large multicenter trials have evaluated the benefit of different medical and surgical therapies to prevent stroke. However, the application of trial results to clinical practice remains uncertain for some areas of stroke prevention and has been discussed passionately among international experts. As part of a worldwide survey, the purpose of this analysis was to provide an informative and comparative view of the current practice of leading experts in North America (NA) and Western Europe (WE), where most of the large prevention trials have been performed. METHODS The survey was performed worldwide among 185 neurologists who are currently leading the discussions of stroke prevention practices. It contained questions on the use of antiplatelet agents, oral anticoagulation, and surgery for the prevention of ischemic stroke. The population of this present analysis is the two groups of experts from WE (n=73) and NA (n=48) exclusively. RESULTS Of each group, >90% responded to the survey. Nearly all respondents reported prescribing aspirin in patients at risk of atherothrombotic stroke, but significant differences between NA and WE are shown by the recommended doses (P<.0001): aspirin doses of >500 mg daily are given exclusively by American participants (36%), whereas doses <200 mg are recommended only in Europe (51%). Eighty-six percent of American versus 59% of European respondents reported using ticlopidine as their second choice (P<.005), and 23% of respondents from WE used warfarin compared with 5% from NA (P<.05). The reported use of anticoagulants in patients with atrial fibrillation increased in accordance with the patient's individual risk of stroke, but respondents from WE were more reluctant to use anticoagulants in patients older than 75 years. Relatively higher target international normalized ratio values were reported by European respondents. Nearly all participants recommend carotid endarterectomy in patients with symptomatic carotid stenosis. The use of carotid endarterectomy in asymptomatic patients was significantly more common among responding experts from NA (48% versus 28%; P<.05), particularly in patients with >95% stenosis (89% versus 53%; P<.0005). CONCLUSIONS This analysis shows significant differences in several areas of stroke prevention practices between leading experts from NA and WE. These differences may be explained partly by divergent results of trials from the two continents, but in some areas of controversy currently available trial data are not sufficient to form an international consensus to guide daily clinical practice.
Collapse
Affiliation(s)
- F Masuhr
- University Department of Neurology, Charité Medical School, Berlin, Germany
| | | | | |
Collapse
|
1062
|
Abstract
Antiplatelet drugs are used in a wide range of disorders, either as sole agents or as adjuncts to other therapies. Aspirin has been shown to be clinically effective in a number of ischaemic conditions and has been in use for many years. The newer agents, ticlopidine and clopidogrel (which are thought to inhibit ADP-mediated platelet reactions) are also effective and may prove to be superior to aspirin in certain indications. However, ticlopidine in particular has a different spectrum of side-effects, which may eventually limit its widespread use. The Gp IIb/IIIa antagonists have been most extensively investigated in the acute coronary syndromes, and shown to significantly improve outcome. Most of these studies have utilized agents which need to be given parenterally, and subsequently oral compounds are currently being developed. A number of other antiplatelet drugs such as prostacyclin and its analogues, as well as thromboxane inhibitors have been studied over the years, but overall they have failed to demonstrate any real clinical advantage.
Collapse
Affiliation(s)
- J E Joseph
- University College London Medical School, Department of Haematology, UK
| | | |
Collapse
|
1063
|
|
1064
|
Stroke. Brain Pathol 1997. [DOI: 10.1111/j.1750-3639.1997.tb01031.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
1065
|
Abstract
It is the elderly who carry the burden of stroke. Whilst 130,000 people suffer a stroke in the UK every year, nearly three quarters of these cases occur over the age of 65 and nearly half occur over the age of 75. As the proportion of elderly in the population continues to grow, inevitably this burden will increase. With Scotland probably experiencing the highest stroke incidence in the UK and stroke already accounting for 5.5% of total hospital costs, challenges clearly lie ahead for the health service and Scottish society as a whole. The extent to which we are able to meet this challenge is becoming clearer. Thus far, therapeutic advance has been rather "low-tech", with organisation of services and the appropriate use of existing interventions showing modest and, just occasionally, dramatic benefits. In contrast, the high hopes raised by many "high-tech" solutions have largely been dashed or remain promising but unproven.
Collapse
Affiliation(s)
- N U Weir
- Department of Clinical Neurosciences, Western General Hospital, Edinburgh.
| | | |
Collapse
|
1066
|
Rosendaal FR, Algra A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1997; 150:85, 87. [PMID: 9260863 DOI: 10.1016/s0022-510x(97)05416-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
1067
|
Gibaldi M. Prevention and treatment of stroke: where do we stand? J Clin Pharmacol 1997; 37:784-90. [PMID: 9549631 DOI: 10.1002/j.1552-4604.1997.tb05625.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M Gibaldi
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle 98195, USA
| |
Collapse
|
1068
|
|
1069
|
5. Primary endpoints. J Neurol Sci 1997. [DOI: 10.1016/s0022-510x(97)90043-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
1070
|
|
1071
|
Humphreys DM. Antiplatelet therapy in ischaemic events. Lancet 1997; 349:1914. [PMID: 9217784 DOI: 10.1016/s0140-6736(05)63916-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
1072
|
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997. [PMID: 9186381 DOI: 10.1016/s0140-6736(97)04010-5] [Citation(s) in RCA: 714] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Aspirin is effective in the treatment of acute myocardial infarction and in the long-term prevention of serious vascular events in survivors of stroke and myocardial infarction. There is, however, no reliable evidence on the effectiveness of early aspirin use in acute ischaemic stroke. METHODS The Chinese Acute Stroke Trial (CAST) was a large randomised, placebo-controlled trial of the effects in hospital of aspirin treatment (160 mg/day) started within 48 h of the onset of suspected acute ischaemic stroke and continued in hospital for up to 4 weeks. The primary endpoints were death from any cause during the 4-week treatment period and death or dependence at discharge, and the analyses were by intention to treat. 21,106 patients with acute ischaemic stroke were enrolled in 413 Chinese hospitals at a mean of 25 h after the onset of symptoms (10,554 aspirin, 10,552 placebo). 87% had a CT scan before randomisation. It was prospectively planned that the results would be analysed in parallel with those of the concurrent. International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. FINDINGS There was a significant 14% (SD 7) proportional reduction in mortality during the scheduled treatment period (343 [3.3%] deaths among aspirin-allocated patients vs 398 [3.9%] deaths among placebo-allocated patients; 2p = 0.04). There were significantly fewer recurrent ischaemic strokes in the aspirin-allocated than in the placebo-allocated group (167 [1.6%] vs 215 [2.1%]; 2p = 0.01) but slightly more haemorrhagic strokes (115 [1.1%] vs 93 [0.9%]; 2p > 0.1). For the combined in-hospital endpoint of death or non-fatal stroke at 4 weeks, there was a 12% (6) proportional risk reduction with aspirin (545 [5.3%] vs 614 [5.9%]; 2p = 0.03), an absolute difference of 6.8 (3.2) fewer cases per 1000. At discharge, 3153 (30.5%) aspirin-allocated patients and 3266 (31.6%) placebo-allocated patients were dead or dependent, corresponding to 11.4 (6.4) fewer per 1000 in favour of aspirin (2p = 0.08). INTERPRETATION There are two major trials of aspirin in acute ischaemic stroke. Taken together, CAST and the similarly large IST show reliably that aspirin started early in hospital produces a small but definite net benefit, with about 9 (SD 3) fewer deaths or non-fatal strokes per 1000 in the first few weeks (2p = 0.001), and with 13 (5) fewer dead or dependent per 1000 after some weeks or months of follow-up (2p < 0.01).
Collapse
|
1073
|
|
1074
|
Narjes H, Müller TH, Weisenberger H, Guth B, Brickl R. Inhibition of platelet aggregation as a surrogate marker. J Clin Pharmacol 1997; 37:59S-64S. [PMID: 9048286 DOI: 10.1177/009127009703700123] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Using acetylsalicylic acid-dipyridamole, a combined thromboxane receptor antagonist-thromboxane synthase inhibitor, and a fibrinogen receptor antagonist as examples, this article discusses the predictive value of several methods that may be employed in the evaluation of antiaggregatory effects and their suitability as surrogate markers for the planning of patient studies. Platelet aggregation in various ex vivo tests and the effects of drugs on these tests were investigated using platelet aggregation in platelet-rich plasma and in whole blood, and in thrombus formation on a thrombogenic surface. Drug-induced inhibition of platelet aggregation is based on the modulation of metabolic processes or interactions at the membrane-receptor level. These effects must be assessed by methods adapted specifically to each mode of action, for example, mediator synthesis inhibition (cyclooxygenase), thromboxane receptor antagonism-thromboxane synthase inhibition, or fibrinogen receptor blockade. Thus a combination of both general and specific methods adapted to the respective mode of action of the test substance can serve as surrogate markers of drug efficacy for the efficient planning of clinical trials.
Collapse
Affiliation(s)
- H Narjes
- Dr. K. Thomae GmbH, Biberach, Germany
| | | | | | | | | |
Collapse
|